Jean Jacques Bienaime - Feb 27, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Feb 27, 2024
Transactions value $
-$90,350
Form type
4
Date filed
2/29/2024, 05:05 PM
Previous filing
Feb 12, 2024
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +82.7K +19.71% $0.00 502K Feb 27, 2024 Direct F1, F2, F3
transaction BMRN Common Stock Award $0 +36K +7.16% $0.00 538K Feb 27, 2024 Direct F1, F3, F4
transaction BMRN Common Stock Award $0 +24.9K +4.63% $0.00 563K Feb 27, 2024 Direct F1, F3, F5
transaction BMRN Common Stock Sale -$90.4K -1K -0.18% $90.35 562K Feb 27, 2024 Direct
holding BMRN Common Stock 247K Feb 27, 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Feb 27, 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 Feb 27, 2024 Shares held as UTMA custodian for child 2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2 Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3 Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
F4 Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F5 Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.